Cryopreserved amniotic membrane in the treatment of diabetic foot ulcers: a case series

• DOI: 10.12968/jowc.2018.27.12.806
• Publication Date: 2018-12-17T17:45:05Z
• Authors: Mónica Rodríguez ...; Francisco J. Nicolás; Ana M. García-Her...; Cristina Fuente Mora; Miguel Blanquer; Patricio J. Alcaraz; Sonia Almansa; Guadalupe Ruiz Me...; Ma Dolores López ...; María C. Algueró; Carmen L. Insausti; Antonio Piñero; José M. Moraleda; Gregorio Castellanos
• Keywords: Adult; Aged, 80 and over; Cryopreservation; Male; Wound Healing; Adolescent; Middle Aged; Allografts; Diabetic Foot; 3. Good health; Young Adult; 03 medical and health sciences; Treatment Outcome; 0302 clinical medicine; Spain; Humans; Female; Amnion; Prospective Studies; Aged

Objective: The amniotic membrane (AM) is a tissue with low immunogenity and high therapeutic potential due to its anti-inflammatory, anti-fibrotic and antimicrobial effects. This paper describes the use of cryopreserved amniotic membrane allografts to treat diabetic foot ulcers (DFUs) in patients with diabetes. Method: In this case series, AM was processed to obtain a final medicinal product: cryopreserved amniotic membrane. cryopreserved AM was applied every 7–10 days until total epithelialisation of the DFUs. Results: A total of 14 patients with DFUs (median size: 12.30cm, (range: 0.52–42.5cm2) were treated and followed up until complete closure (median time: 20 weeks, range: 7–56 weeks). Patients received 4–40 AM applications. All patients in this study achieved complete epithelialisation of the wound. No adverse events were observed. Conclusion: AM is a feasible and safe treatment in complex DFUs. Furthermore, the treatment is successful in achieving epithelialisation of long-evolution, unhealed wounds resistant to conventional therapies.